Compounding pharmacies occupy a unique position in the Australian pharmaceutical landscape. For a broader overview of pharmaceutical cold chain requirements, see our guide to cold chain packaging for vaccines and biologics. Unlike commercial pharmaceutical manufacturers producing standardised registered products, compounding pharmacies prepare individualised medicines — a specific dose, formulation, or combination not available as a commercially registered product — for specific patients on prescription. This individualisation is the value proposition. It is also what makes cold chain management for compounded medicines both more challenging and more consequential than for many other pharmaceutical applications.
A compounded product has no post-market surveillance safety net. There is no batch testing data from a validated commercial process, no pharmacokinetic study establishing stability across temperature ranges, and no Therapeutic Goods Administration (TGA) review of manufacturing conditions. The compounding pharmacist’s own quality systems — including cold chain control — are the primary safeguard of product integrity.
Regulatory Framework for Compounding in Australia
Compounding pharmacy in Australia operates under a dual regulatory framework:
- State and Territory pharmacy legislation governs who can compound and under what conditions
- TGA exemptions under the Therapeutic Goods Act 1989 (particularly Section 41 exemptions) allow compounding without product registration, subject to conditions including that compounding is based on a valid prescription
The Pharmacy Board of Australia’s guidelines on compounding — and the broader cold chain compliance obligations under TGA and FSANZ — set professional standards that include requirements for appropriate storage and labelling. Products that require refrigerated storage must be labelled accordingly and must be stored and transported in a manner that maintains required temperatures.
Large-scale compounding operations — sometimes called “manufacturing compounders” — may operate under TGA manufacturing licences under a separate regulatory pathway, with more rigorous GMP requirements including formal cold chain validation.
Temperature Requirements for Common Compounded Preparations
Hormone Preparations (2–8°C)
Compounded bioidentical hormone preparations — including oestradiol, progesterone, testosterone, and DHEA in customised doses, delivery systems, or combinations — are among the most commonly compounded categories. Many of these preparations require refrigerated storage (2–8°C) to maintain stability, particularly:
- Aqueous gels and creams with protein or peptide actives
- Sublingual troches and sustained-release preparations with temperature-sensitive excipients
- Injectable hormone preparations in solution (which must also meet sterility requirements)
Compounded Injectables (2–8°C)
Sterile compounding — preparing injectable medicines — is the highest-risk compounding activity and the most demanding from a cold chain perspective. Compounded injectables may include:
- Oncology drugs not commercially available or in required concentrations
- Antibiotic solutions for OPAT (outpatient parenteral antibiotic therapy) programmes
- Epidural and intrathecal preparations for pain management
- Veterinary injectables in non-standard concentrations
Compounded injectables for OPAT are a specific high-volume application. Patients on OPAT receive home-based intravenous antibiotic therapy over weeks, typically delivered weekly or fortnightly by the compounding pharmacy. Each delivery must maintain 2–8°C from the pharmacy to the patient’s home. For OPAT patients in outer suburban or regional locations, transit times may be 1–3 hours in ambient conditions, requiring validated cold chain packaging for each delivery.
Compounded Oral Liquids (2–8°C or Room Temperature)
Paediatric oral liquid preparations — often compounded because the commercially available dosage form is not suitable for paediatric patients — may or may not require refrigeration depending on the active ingredient and formulation. Pharmacists preparing these products typically follow published stability guidelines (such as the Paediatric Formulary) that specify required storage conditions.
Compounded Preparations Requiring Colder Temperatures
Some compounded preparations require storage colder than 2–8°C. This is uncommon but includes:
- Certain peptide preparations (BPC-157, thymosin, and other research peptides compounded for specific practitioners)
- Temperature-sensitive growth factors
- Preparations incorporating active pharmaceutical ingredients with documented low-temperature stability requirements
Preparations requiring -20°C or below require dry ice shipping rather than standard gel packs — an area covered in depth in our article on cryogenic cold chain for biotechnology and cell therapy. — an important distinction for pharmacies that have not previously shipped frozen products.
Practical Cold Chain Challenges for Compounding Pharmacies
Last-Mile Delivery
The growth of direct-to-patient delivery by compounding pharmacies (a challenge shared with the broader cold chain for e-commerce sector) — driven by the increase in telehealth prescribing and patient demand for home delivery — has created cold chain challenges that many pharmacy operations were not previously equipped to manage. A compounding pharmacy operating from a metropolitan location may now be delivering to patients across the state, including regional and rural areas where standard courier services do not have cold chain capability.
Options for direct-to-patient cold chain delivery include:
- Contracted cold chain couriers: specialised pharmaceutical courier services with validated cold chain capability; more expensive but appropriate for high-value or sensitive preparations
- Standard couriers with validated insulated packaging: for shorter transits where validated packaging provides adequate temperature protection; must be validated for the specific transit time and worst-case ambient temperature
- Click-and-collect with in-store cold storage: patient collects from a depot or partner pharmacy rather than receiving home delivery; simplifies cold chain but reduces convenience
Packaging Selection
For standard 2–8°C products delivered within same-day or overnight transit times, insulated carriers with pre-conditioned gel packs provide adequate thermal protection. Selection criteria:
- Insulation R-value: higher R-value extends the holding time but increases packaging cost and weight (see our guide to R-values in insulated packaging)
- Gel pack mass: more gel pack thermal mass extends holding time; right-size for the transit scenario
- Gel pack temperature: 0°C gel packs can freeze sensitive preparations. Follow our refrigerant pack pre-conditioning protocol to condition gel packs to 4°C before packing. if placed in direct contact; use a cardboard buffer layer or use gel packs pre-conditioned to 4°C
- Box size: excessive air space reduces efficiency; match box volume to product size
Documentation and Excursion Management
Compounding pharmacy quality systems should include:
- Documented procedures for outgoing cold chain shipments, including packaging procedures and gel pack conditioning
- Temperature monitoring for high-value or high-risk shipments, using dataloggers or indicator cards
- A documented excursion response procedure — what happens when a delivery is delayed or a temperature indicator shows excursion
- Communication with the prescribing practitioner when there is any question about product integrity
Stability Data and Labelling
Unlike registered products, compounded preparations may not have published stability data covering temperature excursions. Pharmacists should document the stability basis for each compounded preparation and label products clearly with storage requirements (e.g., “Store between 2°C and 8°C. Do not freeze. Use by [date].”). When stability data is limited, more conservative expiry dating and more rigorous cold chain control are appropriate risk management responses.
Building a Cold Chain Quality System for Compounding
For compounding pharmacies developing or upgrading their cold chain quality system, the key components are:
- Inventory of cold-chain products and their specific temperature requirements
- Mapping of delivery routes and maximum expected transit times and ambient temperatures
- Selection and validation of packaging systems for each delivery scenario
- Documented procedures for packing, labelling, and courier handoff
- Monitoring approach — routine vs. high-risk shipment monitoring
- Excursion response procedure — who decides on product disposition and how
- Training records for staff involved in packing and dispatch
Dry Chill supplies pharmaceutical-grade cold chain packaging, gel packs, and dataloggers to compounding pharmacies across Australia. For help selecting the right cold chain solution for your specific preparations and delivery routes, contact our team or order a sample pack to test with your products before committing to volume.